Skip to content

Pre-Tax Income at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$39M-80.6%
AptarGroup logo
AptarGroupATR
$93.77M-11.5%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$180.33M+25.4%
AVT
AvantorAVTR
$81.2M-0.6%
Dow logo
DowDOW
$871M+232%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
$181M+86.6%

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$23.72B+32.5%
Enterprise value$23.6B+33.4%
P/E42×+5.3×
P/S7.1×+1.1×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The official record: West Pharmaceutical Services’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's pre-tax income?
West Pharmaceutical Services (WST) reported pre-tax income of $180.1M in Q2 2026.
How has West Pharmaceutical Services's pre-tax income changed year-over-year?
West Pharmaceutical Services's pre-tax income increased by 14.7% year-over-year, from $157M to $180.1M.
What is the long-term trend for West Pharmaceutical Services's pre-tax income?
Over 4 years (2021 to 2025), West Pharmaceutical Services's pre-tax income has grown at a -5.4% compound annual growth rate (CAGR), from $748.9M to $600.9M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.